Eric J. Chow,Yan Chen,Gregory T. Armstrong,Laura‐Mae Baldwin,Casey R. Cai,Todd M. Gibson,Melissa M. Hudson,Aaron McDonald,Paul C. Nathan,Jeffrey E. Olgin,Karen L. Syrjala,Emily S. Tonorezos,Kevin C. Oeffinger,Yutaka Yasui,and Yutaka Yasui1Public Health Sciences and Clinical Research Divisions Fred Hutchinson Cancer Research Center Seattle WA2Department of Pediatrics Seattle Children's HospitalUniversity of Washington Seattle WA3University of Alberta Edmonton Alberta Canada4Department of Epidemiology and Cancer Control St. Jude Children's Research Hospital Memphis TN5Department of Family Medicine University of Washington Seattle WA6School of Medicine University of Texas Southwestern Dallas TX7Division of Cancer Epidemiology and Genetics National Cancer Institute Rockville MD8Department of Oncology St. Jude Children's Research Hospital Memphis TN9Department of Pediatrics The Hospital for Sick Children University of Toronto Ontario Canada10Division of Cardiology Department of Medicine University of California San Francisco CA11Division of Cancer Control and Population Science National Cancer Institute Rockville MD12Department of Medicine Duke University Durham NC

Abstract:Background Determine the prevalence and predictors associated with underdiagnosis and undertreatment of modifiable cardiovascular disease (CVD) risk factors (hypertension, dyslipidemia, glucose intolerance/diabetes) among adult survivors of childhood cancer at high risk of premature CVD. Methods and Results This was a cross‐sectional study of adult‐aged survivors of childhood cancer treated with anthracyclines or chest radiotherapy, recruited across 9 US metropolitan regions. Survivors completed questionnaires and in‐home clinical assessments. The comparator group was a matched sample from the National Health and Nutrition Examination Survey. Multivariable logistic regression estimated the risk (odds ratios) of CVD risk factor underdiagnosis and undertreatment among survivors compared with the National Health and Nutrition Examination Survey. Survivors (n=571; median age, 37.7 years and 28.5 years from cancer diagnosis) were more likely to have a preexisting CVD risk factor than the National Health and Nutrition Examination Survey (n=345; P <0.05 for all factors). While rates of CVD risk factor underdiagnosis were similar (27.1% survivors versus 26.1% National Health and Nutrition Examination Survey; P =0.73), survivors were more likely undertreated (21.0% versus 13.9%, P =0.007; odds ratio, 1.8, 95% CI, 1.2–2.7). Among survivors, the most underdiagnosed and undertreated risk factors were hypertension (18.9%) and dyslipidemia (16.3%), respectively. Men and survivors who were overweight/obese were more likely to be underdiagnosed and undertreated. Those with multiple adverse lifestyle factors were also more likely undertreated (odds ratio, 2.2, 95% CI, 1.1–4.5). Greater health‐related self‐efficacy was associated with reduced undertreatment (odds ratio, 0.5; 95% CI, 0.3–0.8). Conclusions Greater awareness of among primary care providers and cardiologists, combined with improving self‐efficacy among survivors, may mitigate the risk of underdiagnosed and undertreated CVD risk factors among adult‐aged survivors of childhood cancer. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03104543. Nonstandard Abbreviations and Acronyms CCSS Childhood Cancer Survivor Study MHLC Multidimensional Health Locus of Control NHANES National Health and Nutrition Examination Survey Clinical Perspective What Is New? Although the prevalence of underdiagnosed cardiovascular disease risk factors (ie, hypertension, dyslipidemia, glucose intolerance/diabetes) was similar between adult‐aged survivors of childhood cancer previously exposed to cardiotoxic cancer therapies and the general population, cancer survivors were nearly twice as likely to be undertreated for these conditions. What Are the Clinical Implications? Greater awareness of the substantially increased risk of cardiovascular disease among cancer survivors and their health care providers, combined with increased health‐related self‐efficacy among survivors and more aggressive control of cardiovascular risk factors by providers, may mitigate this risk. Five‐year survival after a diagnosis of childhood cancer now exceeds 85% with an estimated half‐million survivors of childhood cancer living in the United States. 1 , 2 However, the excess risk of mortality after 5‐year survival remains considerable, 3 with cardiovascular disease (CVD) the leading noncancer cause of premature mortality in this population. 4 , 5 Attributable to cancer treatment–related exposures, survivors of childhood cancer have a >5‐fold increased risk of serious CVD and death, and a greater burden of modifiable CVD risk factors such as hypertension, dyslipidemia, and diabetes compared with the general population. 4 , 5 These modifiable risk factors appear to be synergistic with the cardiotoxic effects of cancer treatments and potentiate survivors' risk of ischemic heart disease and heart failure more than they do in the general population. 5 , 6 Survivors also tend to develop CVD risk factors at younger ages compared with siblings or the general population. 7< -Abstract Truncated-

Cancer mortality in children surviving congenital heart interventions: A study from the Pediatric Cardiac Care Consortium

Outcomes after cancer diagnosis in children and adult patients with congenital heart disease in Sweden: a registry-based cohort study

Congenital Heart Disease and the Risk of Cancer: An Update on the Genetic Etiology, Radiation Exposure Damage, and Future Research Strategies

Cardiotoxicity in Pediatric Cancer Survivorship: Patterns, Predictors, and Implications for Long-term Care

Mortality After Major Cardiovascular Events in Survivors of Childhood Cancer

Outcomes following major thoracoabdominal cancer resection in adults with congenital heart disease

Double Jeopardy: A Distinct Mortality Pattern Among Preterm Infants with Congenital Heart Disease

Influence of Congenital Heart Disease on Survival in Children with Congenital Diaphragmatic Hernia

Survival of Children With Critical Congenital Heart Defects in the National Birth Defects Prevention Study

Abstract 12585: Flexible Modeling of the Association Between Cumulative Exposure to Low-Dose Ionizing Radiation From Cardiac Procedures and Risk of Hematopoietic Cancer in Children With Congenital Heart Disease

Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

Underdiagnosis and Undertreatment of Modifiable Cardiovascular Risk Factors Among Survivors of Childhood Cancer

Characteristics of in-hospital mortality of congenital heart disease (CHD) after surgical treatment in children from 2005 to 2017: a single-center experience

Population-Based Estimates of the Prevalence of Children With Congenital Heart Disease and Associated Comorbidities in the United States

Temporal Trends of Infant Mortality Secondary to Congenital Heart Disease: National CDC Cohort Analysis (1999-2020)

Lympho-hematopoietic malignancies risk after exposure to low dose ionizing radiation during cardiac catheterization in childhood

Trends in mortality risk of patients with congenital heart disease during the COVID-19 pandemic

US Mortality Attributable to Congenital Heart Disease Across the Lifespan From 1999 Through 2017 Exposes Persistent Racial/Ethnic Disparities

Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age

Cardiomyopathy Risk among Childhood Cancer Survivors of African Ancestry and Its Molecular Mechanisms.

Causes of Death after Congenital Heart Surgery in Children